OncoTherapy Science, Inc. (TYO:4564)

OncoTherapy Science Revenue

In the fiscal year ending March 31, 2026, OncoTherapy Science had annual revenue of 808.00M JPY with 7.73% growth. OncoTherapy Science had revenue of 211.00M in the quarter ending March 31, 2026, with 12.83% growth.

• Revenue: 808.00M
• Revenue Growth: +7.73%
• P/S Ratio: 9.97
• Revenue / Employee: 17.19M
• Employees: 47
• Market Cap: 8.06B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	808.00M	58.00M	7.73%
Mar 31, 2025	750.00M	140.00M	22.95%
Mar 31, 2024	610.00M	-524.00M	-46.21%
Mar 31, 2023	1.13B	-19.00M	-1.65%
Mar 31, 2022	1.15B	821.00M	247.29%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 9, 2026

Data Sources Report a data error